Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
Eli Lilly, Novo Nordisk weight-loss drugs could be blockbusters, Barron's says » 09:14
08/13/22
08/13
09:14
08/13/22
09:14
LLY

Eli Lilly

$307.97 /

+7.72 (+2.57%)

, NVO

Novo Nordisk

$107.43 /

-0.7864 (-0.73%)

New weight-loss drugs,…

New weight-loss drugs, known as incretins, from Eli Lilly (LLY) and Novo Nordisk (NVO) have show striking results in studies. If insurers step up to back them, the drugs - and the stocks - could take off, Bill Alpert writes in this week's edition of Barron's. If every hefty American got treated at these drugs' current prices, the annual market for incretins would be a trillion dollars. Insurers can't afford that, of course, and access to the new drugs is highly restricted. But there's plenty of room for prices to come down and still reward Novo and Lilly shareholders, the author notes. Reference Link

ShowHide Related Items >><<
NVO Novo Nordisk
$107.43 /

-0.7864 (-0.73%)

LLY Eli Lilly
$307.97 /

+7.72 (+2.57%)

LLY Eli Lilly
$307.97 /

+7.72 (+2.57%)

08/11/22 Raymond James
ProQR upgraded to Outperform at Raymond James on RNA editing 'conviction'
08/05/22 Morgan Stanley
Eli Lilly recent weakness a buying opportunity, says Morgan Stanley
08/01/22 Jefferies
Concert Pharmaceuticals price target raised to $14 from $9.50 at Jefferies
07/27/22 Benchmark
AbCellera collaboration lowers reliance on Lilly, says Benchmark
NVO Novo Nordisk
$107.43 /

-0.7864 (-0.73%)

08/05/22 Truist
Global Blood could complement any oncology franchise, says Truist
08/04/22 Barclays
Novo Nordisk price target lowered to DKK 825 from DKK 875 at Barclays
08/03/22 Piper Sandler
Piper says Altimmune selloff related to Novo continuing Phase 3 SELECT trial
07/15/22 Morgan Stanley
Novo Nordisk upgraded to Overweight from Equal Weight at Morgan Stanley
NVO Novo Nordisk
$107.43 /

-0.7864 (-0.73%)

LLY Eli Lilly
$307.97 /

+7.72 (+2.57%)

LLY Eli Lilly
$307.97 /

+7.72 (+2.57%)

NVO Novo Nordisk
$107.43 /

-0.7864 (-0.73%)

LLY Eli Lilly
$307.97 /

+7.72 (+2.57%)

NVO Novo Nordisk
$107.43 /

-0.7864 (-0.73%)

LLY Eli Lilly
$307.97 /

+7.72 (+2.57%)

Friday
On The Fly
What You Missed On Wall Street This Morning » 12:11
08/12/22
08/12
12:11
08/12/22
12:11
RIVN

Rivian Automotive

$38.87 /

-0.04 (-0.10%)

, ILMN

Illumina

$208.12 /

-19.52 (-8.57%)

, JNJ

Johnson & Johnson

$166.17 /

-0.88 (-0.53%)

, TOST

Toast

$20.39 /

+2.265 (+12.50%)

, LAW

CS Disco

$13.62 /

-15.345 (-52.99%)

, LFC

China Life Insurance

$7.30 /

-0.21 (-2.80%)

, PTR

PetroChina

$43.46 /

-1.45 (-3.23%)

, SNP

Sinopec

$45.50 /

-1.705 (-3.61%)

, ACH

Aluminum Corp. of China

$8.93 /

-0.24 (-2.62%)

, SHI

Sinopec Shanghai

$15.54 /

-0.53 (-3.30%)

, LNG

Cheniere Energy

$156.49 /

+1.82 (+1.18%)

, AIV

Aimco

$9.63 /

+0.425 (+4.62%)

, HSBC

HSBC

$33.40 /

-0.1 (-0.30%)

, NVS

Novartis

$85.51 /

+0.065 (+0.08%)

, LXRX

Lexicon

$3.14 /

+0.395 (+14.39%)

, GWH

ESS Inc.

$4.93 /

+0.745 (+17.80%)

, LZ

LegalZoom

$13.24 /

+2.07 (+18.53%)

, PAYO

Payoneer Global

$7.09 /

+1.405 (+24.74%)

, CERT

Certara

$17.27 /

-2.98 (-14.72%)

, SMRT

SmartRent

$3.78 /

-1.785 (-32.10%)

, MKFG

Markforged

$2.74 /

-0.365 (-11.76%)

, OLO

Olo

$8.74 /

-4.28 (-32.87%)

, BR

Broadridge

$178.16 /

+8.485 (+5.00%)

, SPB

Spectrum Brands

$69.09 /

-1.28 (-1.82%)

, HNST

Honest Company

$3.87 /

+0.035 (+0.91%)

, VERO

Venus Concept

/

+

, ELF

e.l.f. Beauty

$36.28 /

-0.15 (-0.41%)

, SNOW

Snowflake

$166.28 /

-1.55 (-0.92%)

, CRM

Salesforce

$187.47 /

+0.71 (+0.38%)

, OKTA

Okta

$102.51 /

+0.11 (+0.11%)

, WDAY

Workday

$174.90 /

+8.98 (+5.41%)

, CIEN

Ciena

$54.30 /

+1.4 (+2.65%)

, IIVI

II-VI

$52.77 /

+0.25 (+0.48%)

, SNY

Sanofi

$44.19 /

+0.67 (+1.54%)

, SIX

Six Flags

$23.19 /

+2.07 (+9.80%)

Get caught up quickly on…

ShowHide Related Items >><<
WDAY Workday
$174.90 /

+8.98 (+5.41%)

VERO Venus Concept
/

+

TOST Toast
$20.39 /

+2.265 (+12.50%)

SPB Spectrum Brands
$69.09 /

-1.28 (-1.82%)

SNY Sanofi
$44.19 /

+0.67 (+1.54%)

SNP Sinopec
$45.50 /

-1.705 (-3.61%)

SNOW Snowflake
$166.28 /

-1.55 (-0.92%)

SMRT SmartRent
$3.78 /

-1.785 (-32.10%)

SIX Six Flags
$23.19 /

+2.07 (+9.80%)

RIVN Rivian Automotive
$38.87 /

-0.04 (-0.10%)

PTR PetroChina
$43.46 /

-1.45 (-3.23%)

PAYO Payoneer Global
$7.09 /

+1.405 (+24.74%)

OLO Olo
$8.74 /

-4.28 (-32.87%)

OKTA Okta
$102.51 /

+0.11 (+0.11%)

NVS Novartis
$85.51 /

+0.065 (+0.08%)

MKFG Markforged
$2.74 /

-0.365 (-11.76%)

LZ LegalZoom
$13.24 /

+2.07 (+18.53%)

LXRX Lexicon
$3.14 /

+0.395 (+14.39%)

LNG Cheniere Energy
$156.49 /

+1.82 (+1.18%)

LAW CS Disco
$13.62 /

-15.345 (-52.99%)

JNJ Johnson & Johnson
$166.17 /

-0.88 (-0.53%)

ILMN Illumina
$208.12 /

-19.52 (-8.57%)

IIVI II-VI
$52.77 /

+0.25 (+0.48%)

HSBC HSBC
$33.40 /

-0.1 (-0.30%)

HNST Honest Company
$3.87 /

+0.035 (+0.91%)

GWH ESS Inc.
$4.93 /

+0.745 (+17.80%)

ELF e.l.f. Beauty
$36.28 /

-0.15 (-0.41%)

CRM Salesforce
$187.47 /

+0.71 (+0.38%)

CIEN Ciena
$54.30 /

+1.4 (+2.65%)

CERT Certara
$17.27 /

-2.98 (-14.72%)

BR Broadridge
$178.16 /

+8.485 (+5.00%)

AIV Aimco
$9.63 /

+0.425 (+4.62%)

ACH Aluminum Corp. of China
$8.93 /

-0.24 (-2.62%)

RIVN Rivian Automotive
$38.87 /

-0.04 (-0.10%)

08/12/22 DA Davidson
Rivian Automotive price target raised to $27 from $24 at DA Davidson
08/12/22 Morgan Stanley
Rivian Automotive's liqudity can last through most of FY23, says Morgan Stanley
08/12/22 Mizuho
Rivian Automotive price target lowered to $65 from $70 at Mizuho
07/18/22 Deutsche Bank
Rivian Automotive price target lowered to $46 from $69 at Deutsche Bank
ILMN Illumina
$208.12 /

-19.52 (-8.57%)

08/12/22 Morgan Stanley
Illumina price target lowered to $240 from $350 at Morgan Stanley
08/12/22 BofA
Illumina price target lowered to $200 from $220 at BofA
08/12/22 Piper Sandler
Piper a buyer of Illumina weakness ahead of Genomics Forum
08/12/22 Canaccord
Illumina price target lowered to $380 from $450 at Canaccord
JNJ Johnson & Johnson
$166.17 /

-0.88 (-0.53%)

07/21/22 UBS
Johnson & Johnson price target lowered to $180 from $185 at UBS
07/20/22 SVB Securities
Johnson & Johnson price target lowered to $194 from $200 at SVB Securities
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Citi
Johnson & Johnson price target lowered to $201 from $205 at Citi
TOST Toast
$20.39 /

+2.265 (+12.50%)

08/12/22 Needham
Toast price target raised to $27 from $21 at Needham
08/12/22 KeyBanc
Toast price target raised to $25 from $18 at KeyBanc
05/17/22 Mizuho
Toast price target lowered to $18 from $19 at Mizuho
05/13/22 Needham
Toast price target lowered to $21 from $38 at Needham
LAW CS Disco
$13.62 /

-15.345 (-52.99%)

08/12/22 Canaccord
CS Disco downgraded to Hold at Canaccord as estimates get reset
08/12/22 Stifel
CS Disco price target lowered to $30 from $40 at Stifel
08/12/22 BofA
CS Disco downgraded to Neutral from Buy at BofA
08/12/22 Canaccord
CS Disco downgraded to Hold from Buy at Canaccord
LFC China Life Insurance
$7.30 /

-0.21 (-2.80%)

08/05/22 JPMorgan
China Life Insurance upgraded to Overweight from Neutral at JPMorgan
PTR PetroChina
$43.46 /

-1.45 (-3.23%)

05/23/22 Citi
PetroChina upgraded to Neutral from Sell at Citi
01/04/22 Citi
PetroChina downgraded to Sell from Neutral at Citi
11/29/21 JPMorgan
PetroChina upgraded to Overweight from Underweight at JPMorgan
10/13/21 JPMorgan
PetroChina downgraded to Underweight from Overweight at JPMorgan
SNP Sinopec
$45.50 /

-1.705 (-3.61%)

06/19/22 Goldman Sachs
Sinopec downgraded to Sell from Neutral at Goldman Sachs
05/23/22 Citi
Sinopec downgraded to Sell from Buy at Citi
ACH Aluminum Corp. of China
$8.93 /

-0.24 (-2.62%)

03/23/22 HSBC
Aluminum Corp. of China upgraded to Hold from Reduce at HSBC
01/13/22 Goldman Sachs
Aluminum Corp. of China downgraded to Sell from Buy at Goldman Sachs
SHI Sinopec Shanghai
$15.54 /

-0.53 (-3.30%)

06/28/22 Morgan Stanley
Sinopec Shanghai downgraded to Equal Weight from Overweight at Morgan Stanley
04/19/22 JPMorgan
Sinopec Shanghai downgraded to Underweight from Neutral at JPMorgan
09/27/21 JPMorgan
Sinopec Shanghai initiated with a Neutral at JPMorgan
LNG Cheniere Energy
$156.49 /

+1.82 (+1.18%)

08/05/22 Mizuho
Cheniere Energy price target raised to $167 from $159 at Mizuho
05/31/22 Wells Fargo
Wells Fargo downgrades Cheniere Energy Partners to Underweight on valuation
05/23/22 RBC Capital
Cheniere Energy price target raised to $178 from $151 at RBC Capital
05/12/22 JPMorgan
Cheniere Energy price target raised to $192 from $183 at JPMorgan
AIV Aimco
$9.63 /

+0.425 (+4.62%)

HSBC HSBC
$33.40 /

-0.1 (-0.30%)

08/08/22 RBC Capital
HSBC price target raised to 650 GBp from 590 GBp at RBC Capital
08/03/22 Goldman Sachs
HSBC downgraded to Neutral from Buy at Goldman Sachs
08/03/22 Berenberg
HSBC price target raised to 625 GBp from 560 GBp at Berenberg
08/03/22 UBS
HSBC price target raised to 680 GBp from 635 GBp at UBS
NVS Novartis
$85.51 /

+0.065 (+0.08%)

08/05/22 Truist
Global Blood could complement any oncology franchise, says Truist
08/04/22 Truist
Truist sees Novartis, Vertex as logical suitors for Global Blood
07/20/22 JPMorgan
Novartis price target raised to CHF 81 from CHF 80 at JPMorgan
07/20/22 Piper Sandler
Piper adjusts Ionis' Spinraza royalties estimate following Biogen report
LXRX Lexicon
$3.14 /

+0.395 (+14.39%)

08/12/22 Piper Sandler
Lexicon initiated with an Overweight at Piper Sandler
07/01/22 Citi
Citi disagrees with Lexicon selloff yesterday, ups target to $20
03/01/22 Citi
Lexicon selloff on filing delay a buying opportunity, says Citi
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
GWH ESS Inc.
$4.93 /

+0.745 (+17.80%)

07/13/22 Canaccord
ESS Inc. assumed with a Hold at Canaccord
06/29/22 Chardan
ESS Inc. initiated with a Neutral at Chardan
03/30/22 Deutsche Bank
ESS Inc. initiated with a Hold at Deutsche Bank
03/22/22 Guggenheim
Guggenheim starts ESS Inc. at Buy on flow battery odds of success
LZ LegalZoom
$13.24 /

+2.07 (+18.53%)

08/12/22 Credit Suisse
LegalZoom price target lowered to $19 from $24 at Credit Suisse
07/28/22 Morgan Stanley
LegalZoom downgraded to Underweight on estimate risk at Morgan Stanley
07/28/22 Morgan Stanley
LegalZoom downgraded to Underweight from Equal Weight at Morgan Stanley
07/14/22 Morgan Stanley
LegalZoom price target lowered to $12 from $13 at Morgan Stanley
PAYO Payoneer Global
$7.09 /

+1.405 (+24.74%)

07/14/22 Goldman Sachs
Payoneer Global upgraded to Buy from Neutral at Goldman Sachs
05/13/22 Northland
Payoneer Global price target lowered to $9 from $14 at Northland
05/13/22 Citi
Payoneer Global price target raised to $7.50 from $6.50 at Citi
03/04/22 Needham
Payoneer Global price target lowered to $7 from $13 at Needham
CERT Certara
$17.27 /

-2.98 (-14.72%)

08/10/22 Piper Sandler
Certara price target lowered to $25 from $28 at Piper Sandler
07/15/22 SVB Securities
Certara initiated with an Outperform at SVB Securities (earlier)
07/13/22 Barclays
Certara price target lowered to $24 from $25 at Barclays
07/01/22 Piper Sandler
Certara initiated with an Overweight at Piper Sandler
SMRT SmartRent
$3.78 /

-1.785 (-32.10%)

08/12/22 Cantor Fitzgerald
SmartRent price target lowered to $5.25 from $6.00 at Cantor Fitzgerald
07/22/22 Cantor Fitzgerald
SmartRent assumed with an Overweight at Cantor Fitzgerald
07/19/22 Keefe Bruyette
Bain Capital sold 5% of stake in SmartRent, says Keefe Bruyette
05/25/22 Compass Point
Compass Point starts SmartRent at Buy, sees 'exponential growth potential'
MKFG Markforged
$2.74 /

-0.365 (-11.76%)

06/10/22 Berenberg
Markforged initiated with a Buy at Berenberg
05/13/22 Citi
Markforged price target lowered to $3 from $5 at Citi
12/21/21 Goldman Sachs
Markforged initiated with a Buy at Goldman Sachs
12/14/21 Craig-Hallum
Craig-Hallum bullish on Markforged, initiates with a Buy
OLO Olo
$8.74 /

-4.28 (-32.87%)

08/12/22 RBC Capital
Olo price target lowered to $12 from $17 at RBC Capital
08/12/22 Truist
Olo price target lowered to $16 from $25 at Truist
08/12/22 Piper Sandler
Olo downgraded to Neutral from Overweight at Piper Sandler
08/12/22 Stifel
Olo downgraded to Hold from Buy at Stifel
BR Broadridge
$178.16 /

+8.485 (+5.00%)

08/17/21 JPMorgan
Broadridge price target raised to $197 from $181 at JPMorgan
08/16/21 DA Davidson
Broadridge price target raised to $158 from $152 at DA Davidson
08/13/21 JPMorgan
Broadridge assumed with an Overweight at JPMorgan
SPB Spectrum Brands
$69.09 /

-1.28 (-1.82%)

07/18/22 Oppenheimer
Spectrum Brands price target lowered to $95 from $125 at Oppenheimer
07/18/22 UBS
Spectrum Brands price target lowered to $109 from $119 at UBS
07/18/22 Wells Fargo
Spectrum Brands price target lowered to $100 from $122 at Wells Fargo
07/13/22 Raymond James
Spectrum Brands initiated with a Market Perform at Raymond James
HNST Honest Company
$3.87 /

+0.035 (+0.91%)

06/09/22 Loop Capital
Loop Capital cuts Honest Company to Hold amid pressure reported in mass retail
06/09/22 Loop Capital
Honest Company downgraded to Hold from Buy at Loop Capital
05/16/22 Loop Capital
Honest Company price target lowered to $5 from $8 at Loop Capital
03/28/22 Citi
Honest Company shares look 'awfully cheap' after selloff, says Citi
VERO Venus Concept
/

+

06/24/22 BTIG
Venus Concept price target lowered to $5.50 from $7.00 at BTIG
11/12/21 Stifel
Venus Concept price target trimmed to $2 at Stifel after Q3 miss
ELF e.l.f. Beauty
$36.28 /

-0.15 (-0.41%)

08/12/22 Cowen
e.l.f. Beauty downgraded to Market Perform at Cowen on valuation
08/12/22 Cowen
e.l.f. Beauty downgraded to Market Perform from Outperform at Cowen
08/04/22 Truist
e.l.f. Beauty price target raised to $40 from $35 at Truist
07/21/22 JPMorgan
e.l.f. Beauty price target raised to $35 from $30 at JPMorgan
SNOW Snowflake
$166.28 /

-1.55 (-0.92%)

08/11/22 Guggenheim
Snowflake initiated with a Sell at Guggenheim
08/02/22 BTIG
Snowflake downgraded to Neutral from Buy at BTIG
07/18/22 Piper Sandler
Snowflake price target lowered to $164 from $165 at Piper Sandler
07/12/22 Baird
Baird starts 'revolutionary' Snowflake with Outperform, $200 target
CRM Salesforce
$187.47 /

+0.71 (+0.38%)

08/11/22 Guggenheim
Salesforce initiated with a Sell at Guggenheim
08/09/22 UBS
UBS sees 'downtick' in partner tone ahead of Salesforce earnings
07/18/22 Piper Sandler
Salesforce price target lowered to $220 from $250 at Piper Sandler
06/02/22 Loop Capital
Salesforce price target lowered to $175 from $225 at Loop Capital
OKTA Okta
$102.51 /

+0.11 (+0.11%)

08/11/22 Guggenheim
Okta initiated with a Sell at Guggenheim
08/10/22 DA Davidson
Okta cut to Neutral at DA Davidson on higher sales turnover and competition
08/10/22 DA Davidson
Okta downgraded to Neutral from Buy at DA Davidson
08/03/22 Stifel
Ping Identity downgraded to Hold from Buy at Stifel
WDAY Workday
$174.90 /

+8.98 (+5.41%)

08/11/22 Guggenheim
Workday initiated with a Sell at Guggenheim
07/18/22 Piper Sandler
Workday price target lowered to $175 from $230 at Piper Sandler
05/27/22 DA Davidson
Workday price target lowered to $220 from $250 at DA Davidson
CIEN Ciena
$54.30 /

+1.4 (+2.65%)

08/12/22 Morgan Stanley
Ciena upgraded to Overweight at Morgan Stanley as supply chain improves
08/12/22 Morgan Stanley
Ciena upgraded to Overweight from Equal Weight at Morgan Stanley
08/04/22 MKM Partners
Ciena assumed with a Buy at MKM Partners
07/14/22 JPMorgan
Ciena price target lowered to $62 from $72 at JPMorgan
IIVI II-VI
$52.77 /

+0.25 (+0.48%)

08/12/22 Morgan Stanley
II-VI downgraded to Equal Weight from Overweight at Morgan Stanley
07/25/22 Barclays
II-VI price target lowered to $47 from $65 at Barclays
07/01/22 Craig-Hallum
II-VI price target lowered to $80 from $85 at Craig-Hallum
05/17/22 Piper Sandler
Piper moves to 'more positive stance' on semiconductor stocks
SNY Sanofi
$44.19 /

+0.67 (+1.54%)

08/12/22 Deutsche Bank
Deutsche Bank raises Sanofi to Hold, calls Zantac 'knee-jerk' reaction overdone
08/12/22 JPMorgan
Sanofi may not be liable for any Zantac litigation damages, says JPMorgan
08/12/22 Deutsche Bank
Sanofi upgraded to Hold from Sell at Deutsche Bank
08/11/22 JPMorgan
Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan
SIX Six Flags
$23.19 /

+2.07 (+9.80%)

08/12/22 Deutsche Bank
Six Flags price target lowered to $38 from $56 at Deutsche Bank
08/12/22 Truist
Six Flags price target lowered to $20 from $32 at Truist
08/12/22 Stifel
Six Flags price target lowered to $28 from $35 at Stifel
08/12/22 KeyBanc
Six Flags downgraded to Sector Weight at KeyBanc after 'indefensible' Q2
WDAY Workday
$174.90 /

+8.98 (+5.41%)

VERO Venus Concept
/

+

TOST Toast
$20.39 /

+2.265 (+12.50%)

SPB Spectrum Brands
$69.09 /

-1.28 (-1.82%)

SNY Sanofi
$44.19 /

+0.67 (+1.54%)

SNOW Snowflake
$166.28 /

-1.55 (-0.92%)

SMRT SmartRent
$3.78 /

-1.785 (-32.10%)

SIX Six Flags
$23.19 /

+2.07 (+9.80%)

RIVN Rivian Automotive
$38.87 /

-0.04 (-0.10%)

PTR PetroChina
$43.46 /

-1.45 (-3.23%)

PAYO Payoneer Global
$7.09 /

+1.405 (+24.74%)

OLO Olo
$8.74 /

-4.28 (-32.87%)

OKTA Okta
$102.51 /

+0.11 (+0.11%)

NVS Novartis
$85.51 /

+0.065 (+0.08%)

MKFG Markforged
$2.74 /

-0.365 (-11.76%)

LZ LegalZoom
$13.24 /

+2.07 (+18.53%)

LXRX Lexicon
$3.14 /

+0.395 (+14.39%)

LNG Cheniere Energy
$156.49 /

+1.82 (+1.18%)

LAW CS Disco
$13.62 /

-15.345 (-52.99%)

JNJ Johnson & Johnson
$166.17 /

-0.88 (-0.53%)

ILMN Illumina
$208.12 /

-19.52 (-8.57%)

IIVI II-VI
$52.77 /

+0.25 (+0.48%)

HSBC HSBC
$33.40 /

-0.1 (-0.30%)

HNST Honest Company
$3.87 /

+0.035 (+0.91%)

GWH ESS Inc.
$4.93 /

+0.745 (+17.80%)

ELF e.l.f. Beauty
$36.28 /

-0.15 (-0.41%)

CRM Salesforce
$187.47 /

+0.71 (+0.38%)

CIEN Ciena
$54.30 /

+1.4 (+2.65%)

CERT Certara
$17.27 /

-2.98 (-14.72%)

BR Broadridge
$178.16 /

+8.485 (+5.00%)

  • 12
    Aug
  • 18
    Nov
  • 10
    Nov
  • 22
    Sep
  • 15
    Sep
  • 09
    Sep
SNY Sanofi
$44.19 /

+0.67 (+1.54%)

SNOW Snowflake
$166.28 /

-1.55 (-0.92%)

RIVN Rivian Automotive
$38.87 /

-0.04 (-0.10%)

OKTA Okta
$102.51 /

+0.11 (+0.11%)

NVS Novartis
$85.51 /

+0.065 (+0.08%)

LNG Cheniere Energy
$156.49 /

+1.82 (+1.18%)

LFC China Life Insurance
$7.30 /

-0.21 (-2.80%)

JNJ Johnson & Johnson
$166.17 /

-0.88 (-0.53%)

ILMN Illumina
$208.12 /

-19.52 (-8.57%)

IIVI II-VI
$52.77 /

+0.25 (+0.48%)

HSBC HSBC
$33.40 /

-0.1 (-0.30%)

CRM Salesforce
$187.47 /

+0.71 (+0.38%)

AIV Aimco
$9.63 /

+0.425 (+4.62%)

WDAY Workday
$174.90 /

+8.98 (+5.41%)

TOST Toast
$20.39 /

+2.265 (+12.50%)

SNY Sanofi
$44.19 /

+0.67 (+1.54%)

SNOW Snowflake
$166.28 /

-1.55 (-0.92%)

SMRT SmartRent
$3.78 /

-1.785 (-32.10%)

SIX Six Flags
$23.19 /

+2.07 (+9.80%)

RIVN Rivian Automotive
$38.87 /

-0.04 (-0.10%)

OKTA Okta
$102.51 /

+0.11 (+0.11%)

NVS Novartis
$85.51 /

+0.065 (+0.08%)

LZ LegalZoom
$13.24 /

+2.07 (+18.53%)

LNG Cheniere Energy
$156.49 /

+1.82 (+1.18%)

LAW CS Disco
$13.62 /

-15.345 (-52.99%)

JNJ Johnson & Johnson
$166.17 /

-0.88 (-0.53%)

ILMN Illumina
$208.12 /

-19.52 (-8.57%)

IIVI II-VI
$52.77 /

+0.25 (+0.48%)

HSBC HSBC
$33.40 /

-0.1 (-0.30%)

HNST Honest Company
$3.87 /

+0.035 (+0.91%)

ELF e.l.f. Beauty
$36.28 /

-0.15 (-0.41%)

CRM Salesforce
$187.47 /

+0.71 (+0.38%)

CIEN Ciena
$54.30 /

+1.4 (+2.65%)

WDAY Workday
$174.90 /

+8.98 (+5.41%)

TOST Toast
$20.39 /

+2.265 (+12.50%)

SNOW Snowflake
$166.28 /

-1.55 (-0.92%)

RIVN Rivian Automotive
$38.87 /

-0.04 (-0.10%)

PAYO Payoneer Global
$7.09 /

+1.405 (+24.74%)

OKTA Okta
$102.51 /

+0.11 (+0.11%)

NVS Novartis
$85.51 /

+0.065 (+0.08%)

LNG Cheniere Energy
$156.49 /

+1.82 (+1.18%)

JNJ Johnson & Johnson
$166.17 /

-0.88 (-0.53%)

ILMN Illumina
$208.12 /

-19.52 (-8.57%)

HSBC HSBC
$33.40 /

-0.1 (-0.30%)

HNST Honest Company
$3.87 /

+0.035 (+0.91%)

CRM Salesforce
$187.47 /

+0.71 (+0.38%)

BR Broadridge
$178.16 /

+8.485 (+5.00%)

Recommendations
Sanofi may not be liable for any Zantac litigation damages, says JPMorgan » 07:40
08/12/22
08/12
07:40
08/12/22
07:40
SNY

Sanofi

$43.46 /

-1.74 (-3.85%)

, GSK

GSK plc

$35.75 /

-2.57 (-6.71%)

, HLN

Haleon

$6.29 /

-0.22 (-3.38%)

, PFE

Pfizer

$48.31 /

-1.62 (-3.24%)

JPMorgan analysts Richard…

JPMorgan analysts Richard Vosser and James Gordon note that shares of GSK plc (GSK), Sanofi (SNY), Haleon (HLN) and Pfizer (PFE) have lost a combined market cap of $44B week to date, which they attribute largely to concerns around potential liabilities related to Zantac litigation. They believe the magnitude of this week's market cap hit "likely exceeds even a worst-case scenario" and also believe the market has not fairly attributed any potential Zantac liability between the various companies involved, the analysts tell investors. GSK is likely to have the clearest evidence linking Zantac use to individual named patients given that it sold the product on a prescription basis from 1983, but they still see this week's $12B hit to the company's market cap as a "potential over-reaction." Still, Vosser and Gordon state in their note that they don't see the GSK overhang shifting ahead of the first bellweather case being heard this coming February. In contrast, they believe it is possible that Sanofi may not be liable for any litigation damages given the company's indemnification agreement with Boehringer that is currently under arbitration. Even in the event Sanofi is not fully indemnified, their exposure via OTC sales would likely be lower than GSK and the company's $16.5B loss in market cap this week means an "overly bearish Zantac outlook is now likely priced in," the analysts said. The firm has an Overweight rating on Sanofi shares and a Neutral rating on GSK.

ShowHide Related Items >><<
SNY Sanofi
$43.46 /

-1.74 (-3.85%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

HLN Haleon
$6.29 /

-0.22 (-3.38%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

SNY Sanofi
$43.46 /

-1.74 (-3.85%)

08/12/22 Deutsche Bank
Sanofi upgraded to Hold from Sell at Deutsche Bank
08/11/22 JPMorgan
Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan
08/11/22 Deutsche Bank
Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank
08/09/22 UBS
Sanofi downgraded to Neutral from Buy at UBS
GSK GSK plc
$35.75 /

-2.57 (-6.71%)

08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
08/08/22 UBS
GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS
HLN Haleon
$6.29 /

-0.22 (-3.38%)

07/29/22 Deutsche Bank
Haleon initiated with a Hold at Deutsche Bank
07/25/22 Goldman Sachs
Haleon initiated with a Buy at Goldman Sachs (last week)
PFE Pfizer
$48.31 /

-1.62 (-3.24%)

08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
08/08/22 Cantor Fitzgerald
Global Blood downgraded to Neutral from Overweight at Cantor Fitzgerald
SNY Sanofi
$43.46 /

-1.74 (-3.85%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

SNY Sanofi
$43.46 /

-1.74 (-3.85%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

SNY Sanofi
$43.46 /

-1.74 (-3.85%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

HLN Haleon
$6.29 /

-0.22 (-3.38%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

HLN Haleon
$6.29 /

-0.22 (-3.38%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

Hot Stocks
Pfizer reports 'positive' results from Phase 3 study of 20vPnC » 06:47
08/12/22
08/12
06:47
08/12/22
06:47
PFE

Pfizer

$48.31 /

-1.62 (-3.24%)

Pfizer announced positive…

Pfizer announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate, 20vPnC, for the prevention of invasive pneumococcal disease caused by the 20 Streptococcus pneumoniae serotypes contained in the vaccine for the pediatric population. The study had two co-primary objectives, associated with immunogenicity responses one month after the third and fourth doses of the four-dose vaccination series, respectively: non-inferiority of the percentage of participants with predefined serotype-specific immunoglobin G concentrations after Dose 3 and NI of IgG geometric mean concentrations after Dose 4. All 20 serotypes met the co-primary objective of NI of IgG GMCs after Dose 4. Fourteen of the 20 serotypes met the co-primary objective of NI of the percentage of participants with predefined IgG levels after Dose 3 (two serotypes missed by a wider margin while four narrowly missed), and all serotypes met noninferiority for the key secondary objective of IgG GMCs after Dose 3. All 20 serotypes elicited robust functional responses and increases in antibody responses after Dose 4, with the totality of data supporting the potential benefit of all serotypes in this 20-valent vaccine candidate. Overall, the safety profile of the 20vPnC candidate was consistent with Prevnar 13 given in the same schedule. A similar percentage of infants receiving either vaccine experienced local reactions (pain at the injection site, redness, and swelling), fever, and other systemic events. The study also met non-inferiority objectives for responses to co-administered routinely used pediatric vaccines. Based on the totality of positive safety and immunogenicity data, Pfizer plans to submit a supplemental Biologics License Application by the end of this year, subject to discussions with the U.S. FDA. Pfizer will seek to present and publish outcomes from this clinical trial at a future date once safety and immunogenicity data have been fully analyzed. Additional top-line results from other pediatric 20vPnC clinical trials are expected to read out in the second half of 2022, with discussions with other regulatory bodies planned once those pivotal data become available.

ShowHide Related Items >><<
PFE Pfizer
$48.31 /

-1.62 (-3.24%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

08/11/22 JPMorgan
Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan
08/11/22 Deutsche Bank
Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank
08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
08/08/22 Cantor Fitzgerald
Global Blood downgraded to Neutral from Overweight at Cantor Fitzgerald
PFE Pfizer
$48.31 /

-1.62 (-3.24%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

Thursday
Hot Stocks
Haleon says it is not a party to any Zantac claims » 17:22
08/11/22
08/11
17:22
08/11/22
17:22
HLN

Haleon

$6.29 /

-0.22 (-3.38%)

, GSK

GSK plc

$35.75 /

-2.57 (-6.71%)

, PFE

Pfizer

$48.31 /

-1.62 (-3.24%)

Haleon (HLN) released a…

Haleon (HLN) released a statement noting the recent volatility in its share price and is aware of market speculation on Haleon's potential liability in respect of Zantac product liability litigation. "Haleon is not aware of any material developments in relation to the Zantac litigation since the Haleon prospectus was issued on 1 June 2022," the company said. "Haleon is not a party to any of the Zantac claims. Haleon never marketed Zantac in any form in the U.S. Haleon is not primarily liable for any OTC or prescription claims. To the extent GSK (GSK) and/or Pfizer (PFE) are held liable in respect of OTC Zantac during the periods outlined below, Haleon may be required to indemnify GSK and/or Pfizer, only if the following conditions are met: GSK and/or Pfizer are unable to recover in respect of OTC Zantac from any third parties who are ahead of Haleon and who have given indemnities under previous transfers of rights to OTC Zantac; and Haleon is determined to be liable under the indemnification provisions among Haleon, Pfizer and GSK."

ShowHide Related Items >><<
PFE Pfizer
$48.31 /

-1.62 (-3.24%)

HLN Haleon
$6.29 /

-0.22 (-3.38%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

HLN Haleon
$6.29 /

-0.22 (-3.38%)

08/11/22 JPMorgan
Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan
08/11/22 Deutsche Bank
Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank
07/29/22 Deutsche Bank
Haleon initiated with a Hold at Deutsche Bank
07/25/22 Goldman Sachs
Haleon initiated with a Buy at Goldman Sachs (last week)
GSK GSK plc
$35.75 /

-2.57 (-6.71%)

08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
08/08/22 UBS
GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS
PFE Pfizer
$48.31 /

-1.62 (-3.24%)

08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
08/08/22 Cantor Fitzgerald
Global Blood downgraded to Neutral from Overweight at Cantor Fitzgerald
PFE Pfizer
$48.31 /

-1.62 (-3.24%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

HLN Haleon
$6.29 /

-0.22 (-3.38%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

HLN Haleon
$6.29 /

-0.22 (-3.38%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

PFE Pfizer
$48.31 /

-1.62 (-3.24%)

HLN Haleon
$6.29 /

-0.22 (-3.38%)

GSK GSK plc
$35.75 /

-2.57 (-6.71%)

Periodicals
Two died from acute liver failure after use of Novartis' Zolgensma, STAT says » 16:04
08/11/22
08/11
16:04
08/11/22
16:04
NVS

Novartis

$85.81 /

-1.615 (-1.85%)

Novartis this week began…

Novartis this week began notifying physicians and payers about the deaths of two children from acute liver failure over the past few months in Russia and Kazakhstan after they were administered the gene therapy Zolgensma, reported STAT News' Ed Silverman. Reference Link

ShowHide Related Items >><<
NVS Novartis
$85.81 /

-1.615 (-1.85%)

NVS Novartis
$85.81 /

-1.615 (-1.85%)

08/05/22 Truist
Global Blood could complement any oncology franchise, says Truist
08/04/22 Truist
Truist sees Novartis, Vertex as logical suitors for Global Blood
07/20/22 JPMorgan
Novartis price target raised to CHF 81 from CHF 80 at JPMorgan
07/20/22 Piper Sandler
Piper adjusts Ionis' Spinraza royalties estimate following Biogen report
NVS Novartis
$85.81 /

-1.615 (-1.85%)

NVS Novartis
$85.81 /

-1.615 (-1.85%)

NVS Novartis
$85.81 /

-1.615 (-1.85%)

NVS Novartis
$85.81 /

-1.615 (-1.85%)

Recommendations
Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan » 14:50
08/11/22
08/11
14:50
08/11/22
14:50
PRGO

Perrigo

$41.26 /

-0.475 (-1.14%)

, PFE

Pfizer

$48.11 /

-1.82 (-3.65%)

, SNY

Sanofi

$43.79 /

-1.41 (-3.12%)

, GSK

GSK plc

$35.32 /

-2.995 (-7.82%)

, HLN

Haleon

$6.24 /

-0.275 (-4.22%)

JPMorgan analyst Chris…

JPMorgan analyst Chris Schott notes the refocus on Zantac liability that has emerged this week, and driven shares of GSK plc (GSK) and Sanofi (SNY) lower, and says he has been getting a number of questions on potential implications within his coverage, namely regarding Perrigo (PRGO) and Pfizer (PFE). As a store brand manufacturer, Perrigo's preemption and HatchWaxman defenses are "very strong," the company has been dismissed from one federal MDL litigation and is not named in the upcoming Madison IL trial, so he does not see Zantac litigation as a significant risk for Perrigo, Schott tells investors. Pfizer sold its rights to Zantac in 2006 and appears to be "at least partially indemnified" from any liability here by Haleon (HLN), said Schott, who contends that the company's loss of about $10B in market cap on this issue "seems overdone" relative to Pfizer's potential exposure. Schott has an Overweight rating on Perrigo shares and a Neutral rating on Pfizer.

ShowHide Related Items >><<
SNY Sanofi
$43.79 /

-1.41 (-3.12%)

PRGO Perrigo
$41.26 /

-0.475 (-1.14%)

PFE Pfizer
$48.11 /

-1.82 (-3.65%)

HLN Haleon
$6.24 /

-0.275 (-4.22%)

GSK GSK plc
$35.32 /

-2.995 (-7.82%)

PRGO Perrigo
$41.26 /

-0.475 (-1.14%)

05/31/22 Jefferies
Perrigo transferred with a Buy at Jefferies
11/11/21 Raymond James
Perrigo price target lowered to $55 from $59 at Raymond James
10/14/21
Fly Intel: Top five analyst upgrades
10/14/21 Raymond James
Raymond James upgrades Perrigo to buy on HRA deal, tax settlement
PFE Pfizer
$48.11 /

-1.82 (-3.65%)

08/11/22 Deutsche Bank
Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank
08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
08/08/22 Cantor Fitzgerald
Global Blood downgraded to Neutral from Overweight at Cantor Fitzgerald
08/08/22 Oppenheimer
Global Blood Therapeutics downgraded to Perform from Outperform at Oppenheimer
SNY Sanofi
$43.79 /

-1.41 (-3.12%)

08/09/22 UBS
Sanofi downgraded to Neutral from Buy at UBS
08/05/22 Stifel
Sanofi price target raised to EUR 119 from EUR 115 at Stifel
07/29/22 JPMorgan
Sanofi price target raised to EUR 115 from EUR 105 at JPMorgan
GSK GSK plc
$35.32 /

-2.995 (-7.82%)

08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
08/08/22 UBS
GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS
08/05/22 Morgan Stanley
GSK plc resumed with an Equal Weight at Morgan Stanley
HLN Haleon
$6.24 /

-0.275 (-4.22%)

07/29/22 Deutsche Bank
Haleon initiated with a Hold at Deutsche Bank
07/25/22 Goldman Sachs
Haleon initiated with a Buy at Goldman Sachs (last week)
07/25/22 Credit Suisse
Haleon initiated with an Outperform at Credit Suisse (last week)
SNY Sanofi
$43.79 /

-1.41 (-3.12%)

PRGO Perrigo
$41.26 /

-0.475 (-1.14%)

PFE Pfizer
$48.11 /

-1.82 (-3.65%)

GSK GSK plc
$35.32 /

-2.995 (-7.82%)

SNY Sanofi
$43.79 /

-1.41 (-3.12%)

PRGO Perrigo
$41.26 /

-0.475 (-1.14%)

PFE Pfizer
$48.11 /

-1.82 (-3.65%)

GSK GSK plc
$35.32 /

-2.995 (-7.82%)

SNY Sanofi
$43.79 /

-1.41 (-3.12%)

PFE Pfizer
$48.11 /

-1.82 (-3.65%)

HLN Haleon
$6.24 /

-0.275 (-4.22%)

GSK GSK plc
$35.32 /

-2.995 (-7.82%)

PFE Pfizer
$48.11 /

-1.82 (-3.65%)

HLN Haleon
$6.24 /

-0.275 (-4.22%)

GSK GSK plc
$35.32 /

-2.995 (-7.82%)

Hot Stocks
FDA grants regular approval to Novartis' capmatinib for metastatic NSCLC » 13:53
08/11/22
08/11
13:53
08/11/22
13:53
NVS

Novartis

$86.17 /

-1.255 (-1.44%)

On August 10, The FDA…

On August 10, The FDA granted regular approval to capmatinib, marketed as Tabrecta by Novartis, for adult patients with metastatic non-small cell lung cancer, or NSCLC, whose tumors have a mutation leading to mesenchymal-epithelial transition, or MET, exon 14 skipping, as detected by an FDA-approved test. Previously, on May 6, 2020, the Food and Drug Administration granted accelerated approval to capmatinib for the same indication.

ShowHide Related Items >><<
NVS Novartis
$86.17 /

-1.255 (-1.44%)

NVS Novartis
$86.17 /

-1.255 (-1.44%)

08/05/22 Truist
Global Blood could complement any oncology franchise, says Truist
08/04/22 Truist
Truist sees Novartis, Vertex as logical suitors for Global Blood
07/20/22 JPMorgan
Novartis price target raised to CHF 81 from CHF 80 at JPMorgan
07/20/22 Piper Sandler
Piper adjusts Ionis' Spinraza royalties estimate following Biogen report
NVS Novartis
$86.17 /

-1.255 (-1.44%)

NVS Novartis
$86.17 /

-1.255 (-1.44%)

NVS Novartis
$86.17 /

-1.255 (-1.44%)

NVS Novartis
$86.17 /

-1.255 (-1.44%)

On The Fly
Renewed Zantac litigation concerns sinking these big-cap drugmakers » 13:35
08/11/22
08/11
13:35
08/11/22
13:35
GSK

GSK plc

$34.82 /

-3.495 (-9.12%)

, SNY

Sanofi

$43.47 /

-1.73 (-3.83%)

, HLN

Haleon

$6.09 /

-0.42 (-6.45%)

, PFE

Pfizer

$48.21 /

-1.72 (-3.44%)

Shares of GSK plc (GSK),…

ShowHide Related Items >><<
SNY Sanofi
$43.47 /

-1.73 (-3.83%)

PFE Pfizer
$48.21 /

-1.72 (-3.44%)

HLN Haleon
$6.09 /

-0.42 (-6.45%)

GSK GSK plc
$34.82 /

-3.495 (-9.12%)

GSK GSK plc
$34.82 /

-3.495 (-9.12%)

08/12/22 JPMorgan
Sanofi may not be liable for any Zantac litigation damages, says JPMorgan
08/11/22 JPMorgan
Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan
08/11/22 Deutsche Bank
Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank
08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
SNY Sanofi
$43.47 /

-1.73 (-3.83%)

08/12/22 Deutsche Bank
Deutsche Bank raises Sanofi to Hold, calls Zantac 'knee-jerk' reaction overdone
08/12/22 Deutsche Bank
Sanofi upgraded to Hold from Sell at Deutsche Bank
HLN Haleon
$6.09 /

-0.42 (-6.45%)

07/29/22 Deutsche Bank
Haleon initiated with a Hold at Deutsche Bank
PFE Pfizer
$48.21 /

-1.72 (-3.44%)

08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
SNY Sanofi
$43.47 /

-1.73 (-3.83%)

PFE Pfizer
$48.21 /

-1.72 (-3.44%)

GSK GSK plc
$34.82 /

-3.495 (-9.12%)

PFE Pfizer
$48.21 /

-1.72 (-3.44%)

GSK GSK plc
$34.82 /

-3.495 (-9.12%)

SNY Sanofi
$43.47 /

-1.73 (-3.83%)

PFE Pfizer
$48.21 /

-1.72 (-3.44%)

HLN Haleon
$6.09 /

-0.42 (-6.45%)

GSK GSK plc
$34.82 /

-3.495 (-9.12%)

PFE Pfizer
$48.21 /

-1.72 (-3.44%)

HLN Haleon
$6.09 /

-0.42 (-6.45%)

GSK GSK plc
$34.82 /

-3.495 (-9.12%)

Hot Stocks
Sanofi says 'confident in its legal defenses' related to U.S. Zantac litigation » 12:30
08/11/22
08/11
12:30
08/11/22
12:30
SNY

Sanofi

$43.24 /

-1.965 (-4.35%)

, GSK

GSK plc

$34.51 /

-3.805 (-9.93%)

, PFE

Pfizer

$48.08 /

-1.85 (-3.71%)

Sanofi issued the…

Sanofi issued the following media update: "In response to the recent highly speculative news flow regarding the U.S. Zantac litigation at a time when there have not been any material developments, Sanofi remains confident in its legal defenses and wishes to make the following statement, consistent with what has been disclosed previously: On September 13, 2019, FDA issued a statement alerting the public that some ranitidine medicines, including over-the-counter Zantac, contained a nitrosamine impurity called N-nitrosodimethylamine, or NDMA, at low levels. NDMA is a known environmental contaminant found in drinking water, soil, and common foods, including meats, dairy products, and vegetables. People are routinely exposed to small amounts of NDMA every day. FDA subsequently announced that its preliminary testing showed NDMA levels exceeded FDA's allowable limit in some of the samples it tested. Upon receipt of this information, however, Sanofi quickly mobilized, ran additional confirmatory testing, and out of an abundance of caution issued a voluntary recall of all ranitidine Zantac OTC products in the U.S. and Canada. Since 2019, the medical, scientific, and regulatory communities have extensively evaluated the safety of Zantac's active ingredient ranitidine, and the data shows there is no evidence of consumer harm from real-world use of Zantac. Over time, both FDA and the European Medicines Agency have evaluated the available data and found no evidence that ranitidine causes cancer. Regardless of the scientific evidence, within days of FDA's 2019 announcement, purported class actions and personal injury lawsuits were filed in US courts, seeking economic damages or alleging that Zantac caused various cancers. However, given that Sanofi acted responsibly at all times and the lack of scientific support for plaintiffs' claims, Sanofi is fully confident in its defenses to the litigation. Sanofi stands by the safety of the medicine today. Importantly, Sanofi acquired the OTC rights to Zantac less than three years before these lawsuits commenced, and after the medicine had been on the market for more than 35 years. In addition to Sanofi, three other companies that marketed Rx and/or branded OTC Zantac over time -- GSK, Pfizer, and Boehringer Ingelheim -- are also named as defendants in these actions. Other additionally named defendants have included dozens of generic manufacturers, retailers, and pharmaceutical distributors. The first trial that may involve Sanofi as a defendant is currently scheduled for February 2023 as a part of the California state court proceedings. Sanofi is not a defendant in many of the other cases currently set for trial. Sanofi's sales of Zantac account for only a very small percentage of the product's total sales over the 35+ years that Rx and OTC Zantac was available. Potential historical brand liability was not all passed to Sanofi upon its acquisition of Zantac. Sanofi acquired the marketing rights to Zantac from Boehringer Ingelheim in 2017. Boehringer Ingelheim continued to manufacture Zantac during the period Sanofi marketed the product. As to the respective indemnification rights and obligations of Sanofi in the context of its acquisition of the product from Boehringer Ingelheim, those obligations are being disputed between the parties in the arbitration. The arbitration award is expected to be rendered around year-end 2022. Regardless of the arbitration outcome, the legal defenses in the US litigation are strong. As of August 1, 2022, Sanofi was aware of approximately 2,850 personal injury plaintiffs across both state and federal jurisdictions with filed cases naming Sanofi in addition to other defendants. When factoring in additional Zantac cases that do not involve Sanofi, Sanofi is aware of approximately 3,450 total personal injury plaintiffs across all jurisdictions. There are other potential personal injury claimants who, in lieu of filing a court case, have instead joined a registry of "unfiled" claims established by the federal MDL court. The data on these potential cases remain preliminary and unverified and subject to change. It remains unknown how many unfiled claimants who have participated in the Registry may file suit, or whether any of those claimants will name Sanofi as a defendant in any such suits. Over time, the number of unfiled claims alleging either Rx and/or OTC use and implicating a variety of defendants in these actions has exceeded 150,000 - a significant number of these claims, however, do not implicate Sanofi. The science does not support the plaintiffs' claims in this litigation. There is no reliable evidence that Zantac causes any of the alleged injuries under real-world conditions, and Sanofi remains fully confident in its defenses. Given the strength of our case and the uncertainty of future proceedings no contingencies have been established." Reference Link

ShowHide Related Items >><<
SNY Sanofi
$43.24 /

-1.965 (-4.35%)

PFE Pfizer
$48.08 /

-1.85 (-3.71%)

GSK GSK plc
$34.51 /

-3.805 (-9.93%)

SNY Sanofi
$43.24 /

-1.965 (-4.35%)

08/11/22 Deutsche Bank
Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank
08/09/22 UBS
Sanofi downgraded to Neutral from Buy at UBS
08/05/22 Stifel
Sanofi price target raised to EUR 119 from EUR 115 at Stifel
07/29/22 JPMorgan
Sanofi price target raised to EUR 115 from EUR 105 at JPMorgan
GSK GSK plc
$34.51 /

-3.805 (-9.93%)

08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
08/08/22 UBS
GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS
08/05/22 Morgan Stanley
GSK plc resumed with an Equal Weight at Morgan Stanley
PFE Pfizer
$48.08 /

-1.85 (-3.71%)

08/09/22 Wells Fargo
Global Blood Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
08/08/22 Cantor Fitzgerald
Global Blood downgraded to Neutral from Overweight at Cantor Fitzgerald
08/08/22 Oppenheimer
Global Blood Therapeutics downgraded to Perform from Outperform at Oppenheimer
SNY Sanofi
$43.24 /

-1.965 (-4.35%)

PFE Pfizer
$48.08 /

-1.85 (-3.71%)

GSK GSK plc
$34.51 /

-3.805 (-9.93%)

SNY Sanofi
$43.24 /

-1.965 (-4.35%)

PFE Pfizer
$48.08 /

-1.85 (-3.71%)

GSK GSK plc
$34.51 /

-3.805 (-9.93%)

SNY Sanofi
$43.24 /

-1.965 (-4.35%)

PFE Pfizer
$48.08 /

-1.85 (-3.71%)

GSK GSK plc
$34.51 /

-3.805 (-9.93%)

PFE Pfizer
$48.08 /

-1.85 (-3.71%)

GSK GSK plc
$34.51 /

-3.805 (-9.93%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.